Comprehensive comparison of the VERSANT® HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR® 1.5 assays on 1000 clinical specimens

Based on our findings from 1000 clinical specimens, we do not see the need to re-establish a baseline value or apply a conversion factor when switching from one assay to the other. Since the majority of our patient population likely is infected with subtype B virus, it is unclear if our findings will apply to other patient populations with a greater incidence of infection with non-B subtypes.